Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global NK Cell Therapy Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Mogamulizumab
  • 1.3.3 Lorvotuzumab Mertansine
  • 1.3.4 Others
• 1.4 Market Segment by Application
  • 1.4.1 Global NK Cell Therapy Market Share by Application (2019-2025)
  • 1.4.2 Cancer
  • 1.4.3 Cardiovascular Diseases
  • 1.4.4 Others
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global NK Cell Therapy Market Size
  • 2.1.1 Global NK Cell Therapy Revenue 2014-2025
  • 2.1.2 Global NK Cell Therapy Sales 2014-2025
• 2.2 NK Cell Therapy Growth Rate by Regions
  • 2.2.1 Global NK Cell Therapy Sales by Regions 2014-2019
  • 2.2.2 Global NK Cell Therapy Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 NK Cell Therapy Sales by Manufacturers
  • 3.1.1 NK Cell Therapy Sales by Manufacturers 2014-2019
  • 3.1.2 NK Cell Therapy Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 NK Cell Therapy Revenue by Manufacturers (2014-2019)
  • 3.2.2 NK Cell Therapy Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global NK Cell Therapy Market Concentration Ratio (CR5 and HHI)
• 3.3 NK Cell Therapy Price by Manufacturers
• 3.4 Key Manufacturers NK Cell Therapy Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into NK Cell Therapy Market
• 3.6 Key Manufacturers NK Cell Therapy Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Mogamulizumab Sales and Revenue (2014-2019)
  • 4.1.2 Lorvotuzumab Mertansine Sales and Revenue (2014-2019)
  • 4.1.3 Others Sales and Revenue (2014-2019)
• 4.2 Global NK Cell Therapy Sales Market Share by Type
• 4.3 Global NK Cell Therapy Revenue Market Share by Type
• 4.4 NK Cell Therapy Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global NK Cell Therapy Sales by Application

6 United States

• 6.1 United States NK Cell Therapy Breakdown Data by Company
• 6.2 United States NK Cell Therapy Breakdown Data by Type
• 6.3 United States NK Cell Therapy Breakdown Data by Application

7 European Union

• 7.1 European Union NK Cell Therapy Breakdown Data by Company
• 7.2 European Union NK Cell Therapy Breakdown Data by Type
• 7.3 European Union NK Cell Therapy Breakdown Data by Application

8 China

• 8.1 China NK Cell Therapy Breakdown Data by Company
• 8.2 China NK Cell Therapy Breakdown Data by Type
• 8.3 China NK Cell Therapy Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World NK Cell Therapy Breakdown Data by Company
• 9.2 Rest of World NK Cell Therapy Breakdown Data by Type
• 9.3 Rest of World NK Cell Therapy Breakdown Data by Application
• 9.4 Rest of World NK Cell Therapy Breakdown Data by Countries
  • 9.4.1 Rest of World NK Cell Therapy Sales by Countries
  • 9.4.2 Rest of World NK Cell Therapy Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Chipscreen Biosciences (China)
  • 10.1.1 Chipscreen Biosciences (China) Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of NK Cell Therapy
  • 10.1.4 NK Cell Therapy Product Introduction
  • 10.1.5 Chipscreen Biosciences (China) Recent Development
• 10.2 Affimed NV (Netherlands)
  • 10.2.1 Affimed NV (Netherlands) Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of NK Cell Therapy
  • 10.2.4 NK Cell Therapy Product Introduction
  • 10.2.5 Affimed NV (Netherlands) Recent Development
• 10.3 Altor BioScience Corporation (USA)
  • 10.3.1 Altor BioScience Corporation (USA) Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of NK Cell Therapy
  • 10.3.4 NK Cell Therapy Product Introduction
  • 10.3.5 Altor BioScience Corporation (USA) Recent Development
• 10.4 Innate Pharma SA (France)
  • 10.4.1 Innate Pharma SA (France) Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of NK Cell Therapy
  • 10.4.4 NK Cell Therapy Product Introduction
  • 10.4.5 Innate Pharma SA (France) Recent Development
• 10.5 Takeda Pharmaceutical (Japan)
  • 10.5.1 Takeda Pharmaceutical (Japan) Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of NK Cell Therapy
  • 10.5.4 NK Cell Therapy Product Introduction
  • 10.5.5 Takeda Pharmaceutical (Japan) Recent Development
• 10.6 Sorrento Therapeutics Inc. (USA)
  • 10.6.1 Sorrento Therapeutics Inc. (USA) Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of NK Cell Therapy
  • 10.6.4 NK Cell Therapy Product Introduction
  • 10.6.5 Sorrento Therapeutics Inc. (USA) Recent Development
• 10.7 NantKwest Inc. (USA)
  • 10.7.1 NantKwest Inc. (USA) Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of NK Cell Therapy
  • 10.7.4 NK Cell Therapy Product Introduction
  • 10.7.5 NantKwest Inc. (USA) Recent Development
• 10.8 Bristol-Myers Squibb (USA)
  • 10.8.1 Bristol-Myers Squibb (USA) Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of NK Cell Therapy
  • 10.8.4 NK Cell Therapy Product Introduction
  • 10.8.5 Bristol-Myers Squibb (USA) Recent Development
• 10.9 NKT Therapeutics (USA)
  • 10.9.1 NKT Therapeutics (USA) Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of NK Cell Therapy
  • 10.9.4 NK Cell Therapy Product Introduction
  • 10.9.5 NKT Therapeutics (USA) Recent Development

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 NK Cell Therapy Sales Channels
  • 11.2.2 NK Cell Therapy Distributors
• 11.3 NK Cell Therapy Customers

12 Market Forecast

• 12.1 Global NK Cell Therapy Sales and Revenue Forecast 2019-2025
• 12.2 Global NK Cell Therapy Sales Forecast by Type
• 12.3 Global NK Cell Therapy Sales Forecast by Application
• 12.4 NK Cell Therapy Forecast by Regions
  • 12.4.1 Global NK Cell Therapy Sales Forecast by Regions 2019-2025
  • 12.4.2 Global NK Cell Therapy Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

In 2019, the market size of NK Cell Therapy is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for NK Cell Therapy.

This report studies the global market size of NK Cell Therapy, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the NK Cell Therapy sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Chipscreen Biosciences (China)
Affimed NV (Netherlands)
Altor BioScience Corporation (USA)
Innate Pharma SA (France)
Takeda Pharmaceutical (Japan)
Sorrento Therapeutics Inc. (USA)
NantKwest Inc. (USA)
Bristol-Myers Squibb (USA)
NKT Therapeutics (USA)

Market Segment by Product Type
Mogamulizumab
Lorvotuzumab Mertansine
Others

Market Segment by Application
Cancer
Cardiovascular Diseases
Others

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the NK Cell Therapy status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key NK Cell Therapy manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of NK Cell Therapy are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025